XNASLUNG
Market cap243mUSD
Dec 24, Last price
6.16USD
1D
-1.60%
1Q
-25.33%
IPO
-85.30%
Name
Pulmonx Corp
Chart & Performance
P/E
—
P/S
3.54
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.89%
Rev. gr., 5y
27.98%
Revenues
69m
+27.98%
Net income
-61m
L+3.26%
CFO
-38m
L-16.58%
Earnings
Feb 19, 2025
Profile
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 68,675 27.98% | 53,662 10.84% | 48,416 47.91% | |||
Cost of revenue | 130,610 | 112,299 | 95,720 | |||
Unusual Expense (Income) | ||||||
NOPBT | (61,935) | (58,637) | (47,304) | |||
NOPBT Margin | ||||||
Operating Taxes | 571 | 353 | 343 | |||
Tax Rate | ||||||
NOPAT | (62,506) | (58,990) | (47,647) | |||
Net income | (60,843) 3.26% | (58,923) 21.09% | (48,661) 50.98% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 2,678 | 2,559 | 4,497 | |||
BB yield | -0.55% | -0.82% | -0.39% | |||
| Debt | ||||||
Debt current | 8,303 | 3,319 | 2,292 | |||
Long-term debt | 40,375 | 28,161 | 33,213 | |||
Deferred revenue | 17,234 | |||||
Other long-term liabilities | (17,234) | 179 | ||||
Net debt | (82,814) | (115,582) | (155,477) | |||
| Cash flow | ||||||
Cash from operating activities | (37,610) | (45,083) | (41,388) | |||
CAPEX | (807) | (1,318) | (3,671) | |||
Cash from investing activities | (2,007) | (4,225) | (46,255) | |||
Cash from financing activities | 21,400 | 2,472 | 4,456 | |||
FCF | (64,673) | (56,540) | (54,649) | |||
| Balance | ||||||
Cash | 117,102 | 141,138 | 180,041 | |||
Long term investments | 14,390 | 5,924 | 10,941 | |||
Excess cash | 128,058 | 144,379 | 188,561 | |||
Stockholders' equity | (408,482) | (348,705) | (289,646) | |||
Invested Capital | 571,295 | 527,095 | 509,377 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 37,975 | 37,097 | 36,129 | |||
Price | 12.75 51.25% | 8.43 -73.71% | 32.07 -53.54% | |||
Market cap | 484,176 54.83% | 312,724 -73.01% | 1,158,670 -52.97% | |||
EV | 401,362 | 197,142 | 1,003,193 | |||
EBITDA | (60,387) | (57,124) | (46,437) | |||
EV/EBITDA | ||||||
Interest | 3,232 | 1,066 | 829 | |||
Interest/NOPBT | ||||||